Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

Inclusion Criteria

• •Received ipilimumab therapy between 03/01/2011 and 6/30/2014
• •Aged 18 years or older at index date (initiation of ipilimumab)
• •Diagnosed with melanoma before index
• •Documented history of an autoimmune disease
• •Have at least 6 months of continuous pharmaceutical and medical benefit enrollment prior to the index
• •Have at least 3 months of continuous pharmaceutical and medical benefit enrollment following and including the index date